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Abstract: (145 words)  
The main metabolism pathway of tryptophan is protein formation, but it can also be 
metabolized into serotonin and kynurenine. Indoleamine 2,3-dioxygenase (IDO) is the 
enzyme that catalyzes the degradation of tryptophan into kynurenine. Mastocytosis is a 
heterogeneous disease characterized by mast cell accumulation in various tissues with 57% of 
patients having gastrointestinal involvement. We studied tryptophan metabolism in 
mastocytosis patients displaying or not gastrointestinal features and healthy subjects (n=26 in 
each group). Mastocytosis patients with digestive symptoms displayed significantly increased 
kynurenine level and IDO activity as compared to healthy controls and mastocytosis patients 
without digestive symptoms. This could be linked to mast cell mediated digestive 
inflammation among patients with mastocytosis. This work is the first focusing on kynurenine 
pathway in a mast cell disease and could help to understand the pathogenesis of digestive 
features in mastocytosis as well as in other mast cell mediated diseases. 
 
Key words: IDO, kynurenine, mastocytosis, serotonin, tryptophan. 
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Introduction 
Tryptophan (TRP) is an essential aminoacid which is the precursor of serotonin (5-HT) and its 
availability is the rate-limiting step in the synthesis of 5-HT (1). TRP is mostly involved in 
protein synthesis but is also the precursor of 5-HT or can be catabolized in the kynurenine 
(KYN) pathway (1). The main enzyme that catalyzes TRP conversion into KYN is 
indoleamine 2,3-dioxygenase (IDO, EC 1.13.11.17) (1)1–4) 
. IDO activity can be induced in various immune cells including mast cells by inflammatory 
cytokines (2) (figure 1). TRP and its metabolites play a role in intestinal immunity, 
inflammation and gut motility through 5-HT (4)(4). 
Mastocytosis is a heterogeneous disease characterized by mast cell accumulation in various 
tissues (6). Clinical manifestations of mastocytosis are related to MC mediators release and to 
pathological MC infiltration (6,7). Mastocytosis patients display disabling gastrointestinal 
symptoms (59%) including(9,10) diarrhoea, bloating, nausea and abdominal pain (9,10)(9,10). 
Although, normal human MC are able to synthesize and release 5-HT (11), mastocytosis  
patients with diarrhea have abnormally low 5-HT (12).  
Our aim was to investigate TRP metabolism in mastocytosis by comparing patients displaying 
gastrointestinal features to healthy controls and mastocytosis patients without gastrointestinal 
features.  
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Patients and methods 
Patients and controls 
Adults with mastocytosis (n=52), as defined by the WHO international consensus criteria (6) 
were enrolled in a prospective national multicentric French study between 2007 and 2013. 
Patients with digestive features (n=26), as defined by our previous report were compared to 
subjects with mastocytosis but without digestive features, matched in sex and age and 
randomly selected in the French mastocytosis center (n=26) (9).  Gastro-intestinal symptoms 
taken into account were bloating, abdominal pain, nausea (≥ 5 times/week), vomiting (≥ 1 
time/week), and liquid stools (> 5 times/week). All patients provided their informed consent. 
The study was approved by the ethics committee at Necker hospital, and was carried out in 
compliance with the precepts of the Helsinki protocol. Healthy subjects with neither digestive 
symptoms nor mastocytosis were used as controls.  
Serum tryptase, plasma tryptophan, whole blood serotonin and plasma kynurenine 
measurements (figure 2).  
Serum total tryptase was measured using fluorescent enzyme-linked immunoassay (Unicap; 
Pharmacia) (14). Whole blood serotonin and plasma TRP rates and KYN  were determined by 
high-performance liquid chromatography (HPLC) (16). IDO activity (= KYN/TRP ratio ) was 
calculated from absolute concentrations of KYN and TRP (17).  
Statistical analysis  
Statistical comparisons were performed using ANOVA and Wilcoxon non parametric tests 
(GraphPad Prism software version 5.01, GraphPad Software Inc., San Diego, CA) when 
appropriate. All reported p values were two-tailed with a significance level of 0.05 
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Results 
Main features of the study population (supplementary tables) 
The characteristics of the patients are described in supplementary Tables. As expected, all 
mastocytosis patients displayed significantly higher tryptase serum rates than healthy controls 
(p<0.0001) (fig.2.A) Seven patients had undergone digestive endoscopic .explorations with 
proven mast cell infiltration on histological biopsies (Supplementary figure 1). In 
mastocytosis patients, digestive features were respectively: diarrhoea (53.9%), abdominal 
pain (42.3%), bloating (34.6%), nausea (19.2%) and vomiting (11.5%).  
Patients with digestive features displayed higher IDO activity and higher levels of 
Kynurenine. 
 Compared to healthy controls, mastocytosis patients displayed lower levels of TRP 
(p<0.0001) independently from GI symptoms. However, only those with gastrointestinal 
symptoms had higher IDO activity compared to controls (Figure 2.B; p<0.001). Moreover, 
KYN and IDO levels were higher in mastocytosis patients with gastrointestinal symptoms 
compared to patients without digestive features (Figure 2.C-D; p = 0.01 and 0.045 
respectively).  
Relationship between digestive features, tryptophan concentrations and IDO activity in 
mastocytosis. 
Patients with more intense abdominal pain (score >5, on a scale from 0 to 10) tend to display 
minor TRP concentrations (p=0.055) and significant higher IDO activity (p = 0.04). No other 
relationship was found between TRP level, IDO activity and other gastro-intestinal symptoms 
(Figure 2.E-F). 
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Discussion 
This is the first report studying TRP metabolism and the kynurenine pathway in mastocytosis 
with related GI symptoms. We found that mastocytosis patients displaying digestive features 
had higher IDO activity and decreased TRP levels as compared to healthy controls and to 
patients without digestive features. The decreased TRP level might be the consequence of an 
activation of the IDO pathway. This hypothesis is supported by the increased kynurenine level 
in mastocytosis patients with intestinal involvement. In these patients, IDO could be induced 
by the release of mast cell mediators in the digestive tract. Mast cells can secrete 
proinflammatory cytokines such as TNF alpha, interleukins 1 and 6, INF alpha (18) and are 
also able to express IDO (11). Moreover, recent work by Kawasaki showed that KYN 
catabolites are able to activate mast cells through an aryl hydrocarbon receptor which could 
stimulate IDO activity in mast cells, leading to kynurenine accumulation (19). The 
consequence could be a vicious circle activating more mast cells that, in turn, secrete 
proinflammatory cytokines leading to IDO activation. 
Interestingly, gastro-intestinal lesions in mastocytosis patients could lead to an increase in 
intestinal permeability and circulating LPS which is known to stimulate proinflammatory 
cytokines and activate IDO, and thus the kynurenine formation (20).  
Recent studies have focused on the role of tryptophan metabolism in irritable bowel syndrome 
(IBS). IBS patients share many features with mastocytosis patients displaying intestinal 
involvement, such as abdominal pain, bloating and infiltration by mast cells in the gut mucosa 
(21)(21)(21). Taken together, it is interesting to speculate that these two clinically close 
entities could share some pathogenenic aspects involving gut mucosal immune homeostasis 
possibly linked to the microbiota (21). 
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The presence of decreased TRP and 5-HT levels in mastocytosis patients could suggest a link 
to functional symptoms described by patients. Antihistaminics could be useful to prevent mast 
cell mediator liberation if they are specific for TPH1. Some authors have suggested the use of 
tryptophan hydroxylase inhibitors for irritable bowel syndrome which could be tried in 
digestive mastocytosis (22). 
In conclusion, this study provides new elements in the pathogenesis of digestive features in 
mastocytosis which could open new therapeutic strategy in these patients as well as in gastro-
intestinal diseases such as IBS that share common pathogenenic aspects.
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Figure legends 
Figure 1. Schematic representation of tryptophan metabolism pathway 
Cytokines (interleukines 1 and 6, TNF ) synthetized by activated mast cells in mastocytosis 
are able to induce the enzyme indoleamine-2,3-dioxygenase (IDO) that catabolizes TRP into 
KYN, thereby reducing the availability of TRP for 5-HT synthesis. 
Figure 2. Tryptophan metabolism in Mastocytosis 
Tryptase level (panel A), Tryptophan level (panel B), Kynurenine level (panel C) and IDO 
activity (panel D) in blood of mastocytosis patients with or without digestive symptoms and 
in healthy controls. Tryptophan level (panel E) and IDO activity (panel F) is associated with 
abdominal pain in mastocytosis patients with gastro-intestinal symptoms. *, p<0.05; ***, 
p<0.001. IDO activity is the result of the ratio KYN/TRP expressed in percentage.  
 
Supplementary figure 1. 
Examples of MC infiltration in the gastrointestinal tract. Panel A. Duodenal mucosa biopsy of 
a patient with mastocytosis showing a huge infiltration by round monomorphic cells 
suggesting mast cells (H&E x200). Panel B. Immunohistochemistry staining with anti-CD117 
antibody showing large aggregates of mast cells in the lamina propria with diffuse expression 
of c-kit (CD117) antibody x200. 
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Supplementary Table 1: Comparison of main features of mastocytosis patients with or 
without digestive symptoms. 
 Digestive symptoms No digestive 
symptoms 
Healthy controls p Digestive symptoms 
vs No digestive 
symptoms 
 n = 26 n = 26 n=26 
Age at diagnosis 
(years) 
median (range) 
 
50 
(25-65) 
40 
(26 – 71) 
50 
(25-65) 
 
0.12 
Female/Male 
 
WHO stage 
     CM 
     ISM 
     ASM 
     SM-AHNMD 
22/4  
                                           
 
3                        
19                     
3 
1 
18/8 
 
0 
23 
2 
1 
22/4 
 
 
- 
- 
- 
- 
0.11 
 
 
 
0.3 
16 
 
 
KIT mutation 
D816V  
No (WT ) 
 
 
 
21  
5 
 
 
 
24 
2 
 
                    
 
- 
- 
 
 
0.22 
Laboratory data,  
median (range) 
Tryptase (ng/L) 
5-HT (nM) 
Tryptophan (µM) 
Kynurenine (µM) 
IDO (%) 
 
 
 
27.2 (11.3 – 257) 
272 (34 – 1278) 
45.8 (22.2– 60) 
3.9  (1.9 – 5.3) 
8.7 (3.1 – 18.1) 
 
 
 
30.5 (2.7 – 161) 
226.5 (49 – 910) 
46.2 (12.2 – 59.2) 
2.9  (1.6 – 4.6) 
6.65 (3.7 – 14.7) 
 
 
 
4.35 (2.8-5.3) 
352.5 (147-708) 
52.4 (48.3-57.3) 
3.4  (1.9 – 4.7) 
6.16 (3.8-9.4) 
 
 
 
0.7 
0.09 
0.6 
0.01 
0.04 
 
Abbreviations: CM: cutaneous mastocytosis; ISM: indolent systemic mastocytosis; ASM: 
agressive systemic mastocytosis; AHNMD: associated clonal haematological non-MC-lineage 
disease. 5-HT: serotonin; IDO: Indoleamine 2,3-dioxygenase;  
1P was calculated according to chi squared Fisher’s exact test or Mann-Whitney test. 
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Supplementary table 2. Main features of mastocytosis patients with digestive features 
Patient 
number 
Age  Sex KIT sequencing WHO 
stage 
Serum 
Tryptase  
Whole 
blood 
5-HT 
Plasma 
Tryptophan 
IDO 
activity 
1 54 F D816V ISM 18.5 219 47 9.2 
2 25 F D816V SM-
AHNMD 
19 653 43 8.8 
3 51 F D816V ASM 32 797 52 7.7 
4 62 F D816V ISM 15.5 436 31.7 13.2 
5 39 M D816V ISM 31.5 429 58 7.1 
6 33 F WT ISM 15.6 173 47 10 
7 57 F D816V ASM 37 226 49 9.4 
8 51 M D816V ISM 48 665 44.5 9.7 
9 39 F D816V ISM 68 1033 61 3.1 
10 63 F D816V ISM 82 34 28 18 
11 62 F D816V ISM 19 203 48 10.4 
12 50 M D816V CM 13 152 49 6.5 
13 50 F WT ISM 200 130 30 8 
14 45 F WT ISM 15 1278 29 8.6 
15 45 F D816V ISM 39 247 57 4.75 
18 
 
16 47 F D816V ISM 177 387 54.5 9.7 
17 65 F D816V ISM 257 250 51 7.5 
18 57 M D816V ISM 228 321 44 6.3 
19 40 F D816V ISM 79 266 41 10.3 
20 43 F D816V ISM 11.4 110 22 17.6 
21 37 F WT ASM 95 192 60 4.3 
22 38 F D816V ISM 21 278 34 8.6 
23 54 F WT ISM 16.5 471 41.6 11.5 
24 53 F D816V ISM 15 310 48 5.2 
25 57 F D816V CM 23 240 45 7.4 
26 43 F D816V CM 11 284 41 9 
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Supplementary table 3. Main features of mastocytosis patients without digestive features 
Patient 
number 
Age  Sex KIT 
sequencing 
WHO stage Serum 
tryptase  
Whol
e 
bloo
d 5-
HT 
Plasma 
Tryptophan 
IDO 
1 37 F D816V ISM 5.5 233 40.5 7.65 
2 31 F D816V ISM 3.8 374 48.6 5.35 
3 60 F D816V ISM 22 95 12.2 14.7 
4 34 F WT ASM 30 157 32.3 10.8 
5 51 F D816V ISM 21.4 393 46.8 6.8 
6 39 F D816V ISM 25 98 35.7 12.9 
7 52 H D816V ISM 31 120 27.9 16.5 
8 46 H D816V ASM 161 289 50 7.2 
9 28 F D816V ISM 8.6 118 37.4 4.2 
10 50 H D816V ISM 47.7 665 44.5 9.6 
11 39 F D816V ISM 30 241 56.6 6.7 
12 36 F D816V ISM 27 910 59.2 4 
13 36 F WT ISM 40 105 44.8 6 
14 44 F D816V ISM 90 221 56.8 4.75 
20 
 
15 32 F D816V ISM 19 335 50.2 5.6 
16 66 H D816V ISM 35.6 85 45.7 6.6 
17 71 H D816V ISM 43 199 49.6 5.3 
18 42 H D816V ISM 47 404 56.7 3.7 
19 48 F D816V ISM 37 128 40.2 6.2 
20 26 H D816V ISM 57 49 47.6 6.7 
21 55 F D816V ISM 80 338 39 4.8 
22 38 H D816V ISM 45 232 49 5.9 
23 41 F D816V ISM 6 156 57.4 4.5 
24 62 H D816V SM-
AHNMD 
152 203 46.8 6.8 
25 35 F D816V ISM 29 242 33.4 10.2 
26 37 F D816V ISM 2.7 241 37 11.1 
 
